PTPN11 and bladder transitional cell carcinoma: As can be seen in Figure 2A, individuals who had elevated expression levels of PTPN11 were significantly linked to poor overall survival (OS) in the following cancers: bladder carcinoma (BLCA) (p = 0.016), breast cancer (p = 0.0013), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (p = 0.0017), LUAD (p = 0.0082), PAAD (p = 0.012), and thyroid carcinoma (THCA) (p = 0.036).